Trawicki Roman
Known title: Executive Vice PresidentCIK: 0001640777
Associated companies
Transaction History
| ZTS | ▲ Buy | Option Exercise | 6,000 | $525K | 3/16/2022 | View on chart |
| ZTS | ▼ Sell | Open Market | 6,000 | $1.1M | 3/16/2022 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 1,639 | $326K | 2/12/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 12,022 | — | 2/12/2022 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 5,651 | $1.1M | 2/12/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 3,486 | — | 2/12/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 3,287 | $241K | 10/1/2021 | View on chart |
| ZTS | ▼ Sell | Open Market | 4,497 | $873K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating
Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.